Boston Partners Takes Position in Harmony Biosciences Holdings, Inc. $HRMY

Boston Partners purchased a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 605,495 shares of the company’s stock, valued at approximately $19,398,000. Boston Partners owned approximately 1.05% of Harmony Biosciences as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Strs Ohio purchased a new stake in shares of Harmony Biosciences in the 1st quarter worth about $587,000. Robeco Institutional Asset Management B.V. purchased a new stake in Harmony Biosciences in the second quarter worth about $1,478,000. CX Institutional increased its stake in shares of Harmony Biosciences by 166.8% during the second quarter. CX Institutional now owns 207,783 shares of the company’s stock valued at $6,566,000 after purchasing an additional 129,916 shares in the last quarter. Woodline Partners LP purchased a new position in shares of Harmony Biosciences during the first quarter valued at approximately $6,035,000. Finally, New Vernon Capital Holdings II LLC boosted its position in shares of Harmony Biosciences by 3,219.0% in the 1st quarter. New Vernon Capital Holdings II LLC now owns 488,424 shares of the company’s stock worth $16,211,000 after purchasing an additional 473,708 shares in the last quarter. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Price Performance

NASDAQ HRMY opened at $34.29 on Friday. Harmony Biosciences Holdings, Inc. has a one year low of $25.52 and a one year high of $40.93. The stock has a 50-day moving average of $29.71 and a 200 day moving average of $32.80. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.72 and a current ratio of 3.75. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of 10.78, a PEG ratio of 0.46 and a beta of 0.85.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.05). Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. The company had revenue of $239.46 million for the quarter, compared to analysts’ expectations of $222.68 million. On average, sell-side analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Needham & Company LLC reduced their price objective on Harmony Biosciences from $48.00 to $41.00 and set a “buy” rating for the company in a research report on Wednesday, September 24th. Weiss Ratings restated a “hold (c)” rating on shares of Harmony Biosciences in a report on Tuesday. Mizuho lifted their price target on Harmony Biosciences from $36.00 to $39.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. UBS Group cut their price objective on shares of Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on shares of Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Harmony Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $44.50.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.